Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 8/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | DHPS | P49366 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30564127 | 1.00 | CYP3A4 (0.47) | CYP3A4AHRPIK3CDRHEBHTR6 | |
| SCHEMBL4796603 | 0.81 | ALDH1A1 (0.52) | CYP3A4AHRPIK3CDRHEBHTR6 | |
| SCHEMBL4572244 | 0.79 | AHR (0.50) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL30089259 | 0.76 | IMPDH2 (0.44) | CYP3A4AHRMAPK1 | |
| SCHEMBL4042175 | 0.76 | IMPDH2 (0.44) | CYP3A4AHRMAPK1 | |
| SCHEMBL29370250 | 0.75 | CYP3A4 (0.62) | CYP3A4MAPK1TRPA1 | |
| SCHEMBL22210 | 0.75 | CYP3A4 (0.62) | CYP3A4MAPK1TRPA1 | |
| SCHEMBL97760 | 0.75 | AHR (0.50) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL4118127 | 0.75 | AHR (0.50) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL25405674 | 0.70 | CYP3A4 (0.47) | CYP3A4AHRMAPK1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118742543-A | Dihydro isoquinoline compound and medical application thereof | 中国科学院上海药物研究所 | 2024-10-01 | — | — | CN | disclosed |
| CN-116789641-A | Dihydro isoquinoline compound and medical application thereof | 中国科学院上海药物研究所 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023174383-A1 | DIHYDROISOQUINOLINE COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2023-09-21 | — | — | WO | disclosed |
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-09-04 | — | — | US | disclosed |
| US-7335678-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBOTT LABORATORIES (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1863777-A | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2006-11-15 | — | — | CN | disclosed |
| US-7074805-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-07-11 | — | — | US | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBVIE INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030158188-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | TRPV1, TMEM109, VIPR1 | CYP3A4 1234/4885AHR 1034/4885PIK3CD 2041/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | CYP3A4 1208/4885AHR 974/4885PIK3CD 2002/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | CYP3A4 1191/4885AHR 1009/4885PIK3CD 2004/4885 |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | TRPV1, TMEM109, GPR55 | CYP3A4 1162/4885AHR 627/4885PIK3CD 2245/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | CYP3A4 1234/4885AHR 1034/4885PIK3CD 2041/4885 |
| US-20030158188-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | CYP3A4 1234/4885AHR 1034/4885PIK3CD 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.